Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  bevacizumab
Find trials that include:  Any drugs shown
Results 1-25 of 82 for your search:
Start Over
Pegylated Liposomal Doxorubicin Hydrochloride with Atezolizumab and/or Bevacizumab in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY009, NCI-2016-01081, NCT02839707
FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: OX4325, NCI-2017-00356, NCT02641639
Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1302.3, NCI-2016-01340, 2015-003718-25, NCT02776683
A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CanStem303C, NCI-2016-01385, 2016-001627-31, BB608-303CRC, NCT02753127
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients with Microsatellite Instability-High Metastatic Colorectal Cancer
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: NRG-GI004, NCI-2016-01961, NRG-GI004/S1610, NCT02997228
Hydroxychloroquine, Fluorouracil, Leucovorin Calcium, Oxaliplatin, and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 07210, NCI-2010-02018, NCT01206530
Bevacizumab, Minocycline Hydrochloride, and Radiation Therapy in Treating Patients with Recurrent Glioma
Status: Active
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: HCI55264, NCI-2012-01118, 55264, NCT01580969
Pazopanib Hydrochloride and Bevacizumab in Treating Patients with Previously Untreated Metastatic Kidney Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 191711, NCI-2012-01247, 13-069, NCT01684397
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: TPI-287-17, NCI-2014-01453, NCT01933815
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBI608-246, NCI-2015-00892, NCT02024607
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 16 and over
Trial IDs: NLG2102, NCI-2014-02063, NCT02052648
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MRZ-108, NCI-2015-00711, NCT02330562
Alectinib and Bevacizumab in Treating Patients with ALK-positive Stage IIIB-IV Non-small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-055, NCI-2015-01704, NCT02521051
Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: ABI-007-PANC-009, NCI-2016-00214, NCT02620800
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-370, NCI-2016-00707, NCT02574078
Osimertinib and Bevacizumab in Treating Patients with Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 19 and over
Trial IDs: 16-033, NCI-2016-01095, NCT02803203
Valproic Acid and Radiation Therapy Followed by Maintenance Valproic Acid and Bevacizumab in Treating Young Patients With Newly Diagnosed High-Grade Gliomas
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 21
Trial IDs: H-24549, NCI-2012-00618, NCT00879437
High-Dose Chemotherapy, Bevacizumab, and Stem Cell Transplant in Treating Patients with Recurrent Germ Cell Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 12 to 65
Trial IDs: 2008-0378, NCI-2011-01631, NCT00936936
Bevacizumab and Erlotinib Hydrochloride in Treating Patients with Hereditary Leiomyomatosis and Advanced Kidney Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-C-0114, NCI-2013-01459, 100114, P10628, NCT01130519
Carboplatin and Bevacizumab in Treating Patients with Recurrent Ependymoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-C-0009, NCI-2011-01283, CERN 09-02, P152432, NCT01295944
Cyclodextrin-Based Polymer-Camptothecin CRLX101 with or without Bevacizumab in Treating Patients with Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 11-485, NCI-2012-01544, NCT01652079
Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin before Surgery in Treating Patients with Stage II-III Rectal Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 3R-12-2, NCI-2013-01069, 3C-12-2, HS-12-00726, ML28263, NCT01871571
Start Over